Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase. Yin W, Wang S, Lu W, Duan T Front Immunol. 2026; 17:1793153. PMID: 42206038. Abstract CommentRecommendBookmarkWatch
